BR112017020131A2 - derivados de 7-(morfolin-4-il)pirazol[1,5-a]pirimidina que são úteis para o tratamento de doenças imunológicas ou inflamatórias ou câncer - Google Patents

derivados de 7-(morfolin-4-il)pirazol[1,5-a]pirimidina que são úteis para o tratamento de doenças imunológicas ou inflamatórias ou câncer

Info

Publication number
BR112017020131A2
BR112017020131A2 BR112017020131-3A BR112017020131A BR112017020131A2 BR 112017020131 A2 BR112017020131 A2 BR 112017020131A2 BR 112017020131 A BR112017020131 A BR 112017020131A BR 112017020131 A2 BR112017020131 A2 BR 112017020131A2
Authority
BR
Brazil
Prior art keywords
cancer
inflammatory diseases
morpholin
pyrazol
useful
Prior art date
Application number
BR112017020131-3A
Other languages
English (en)
Other versions
BR112017020131B1 (pt
Inventor
Dymek Barbara
Zagozda Marcin
Wieczorek Maciej
DUBIEL Krzysztof
Stanczak Aleksandra
Zdzalik Daria
Gunerka Pawel
Sekular Mariola
Dziachan Maciej
Original Assignee
Celon Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celon Pharma S.A. filed Critical Celon Pharma S.A.
Publication of BR112017020131A2 publication Critical patent/BR112017020131A2/pt
Publication of BR112017020131B1 publication Critical patent/BR112017020131B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

trata-se de um composto de fórmula geral (i) em que y representa -ch2- ou >c=0; r1 é selecionado a partir do grupo que consiste em a1, a2 e a3; r2 representa uma porção química de dioxotiomorfolino b1, porção química de piperazinila b2, porção química de azetidinila b3 ou porção química de piperidinila b4; r3 é selecionado a partir do grupo que consiste em h, halogênio e alquila c1 -c4; r4 é selecionado a partir do grupo que consiste em alquila c1 -c4, ciclolquila-c3-c4, alquila-c1 -c4 substituída por alcóxi-c1 -c4 e chf2 e seus sais farmaceuticamente aceitáveis. as composições farmacêuticas que compreendem os ditos compostos e seu uso no tratamento de doenças de sistema imunológico, doenças inflamatórias e câncer.
BR112017020131-3A 2015-04-02 2016-03-30 Composto, seu uso e composição farmacêutica BR112017020131B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL411864A PL236355B1 (pl) 2015-04-02 2015-04-02 Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
PL411864 2015-04-02
PCT/IB2016/051792 WO2016157091A1 (en) 2015-04-02 2016-03-30 7-(morpholin-4-yl)pyrazole[1,5-a]pyrimidine derivatives which are useful for the treatment of immune or inflammatory diseases or cancer

Publications (2)

Publication Number Publication Date
BR112017020131A2 true BR112017020131A2 (pt) 2018-05-29
BR112017020131B1 BR112017020131B1 (pt) 2023-02-28

Family

ID=55650626

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017020131-3A BR112017020131B1 (pt) 2015-04-02 2016-03-30 Composto, seu uso e composição farmacêutica

Country Status (18)

Country Link
US (1) US10138247B2 (pt)
EP (1) EP3277687B1 (pt)
JP (1) JP6665201B2 (pt)
KR (1) KR102559190B1 (pt)
CN (1) CN107743489B (pt)
AU (1) AU2016241568B2 (pt)
BR (1) BR112017020131B1 (pt)
CA (1) CA2978828A1 (pt)
DK (1) DK3277687T3 (pt)
EA (1) EA032826B1 (pt)
ES (1) ES2765642T3 (pt)
HR (1) HRP20192195T1 (pt)
HU (1) HUE047822T2 (pt)
MX (1) MX2017011423A (pt)
PL (2) PL236355B1 (pt)
PT (1) PT3277687T (pt)
SI (1) SI3277687T1 (pt)
WO (1) WO2016157091A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021347913A1 (en) * 2020-09-28 2023-05-18 1ST Biotherapeutics, Inc. Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same
CN114957261B (zh) * 2022-05-17 2023-06-23 重庆文理学院 一种具有抗头颈癌作用的化合物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL191271B1 (pl) * 1996-02-07 2006-04-28 Neurocrine Biosciences Inc Pochodna pirazolopirymidyny i jej zastosowanie oraz kompozycja farmaceutyczna
WO2005062882A2 (en) 2003-12-23 2005-07-14 Activbiotics, Inc Rifamycin analogs and uses thereof
AU2006212457B2 (en) * 2005-02-11 2011-04-14 F. Hoffmann-La Roche Ag Pyrazolo-pyrimidine derivatives as mGLuR2 antagonists
MY146388A (en) * 2006-09-20 2012-08-15 Lilly Co Eli Thiazole pyrazolopyrimidines as crfi receptor antagonists
CN101835779B (zh) * 2007-10-26 2014-01-29 霍夫曼-拉罗奇有限公司 作为pi3激酶抑制剂的嘌呤衍生物
AU2009218515A1 (en) 2008-02-26 2009-09-03 Novartis Ag Heterocyclic compounds as inhibitors of CXCR2
KR20110042153A (ko) * 2008-05-30 2011-04-25 제넨테크, 인크. 퓨린 ｐｉ３ｋ 억제 화합물 및 사용 방법
US20110257170A1 (en) * 2008-10-03 2011-10-20 Merck Serono Sa 4-morpholino-pyrido[3,2-d]pyrimidines
WO2010074284A1 (ja) * 2008-12-26 2010-07-01 味の素株式会社 ピラゾロピリミジン化合物
SG175195A1 (en) * 2009-04-16 2011-11-28 Ct Nac Investigaciones Oncologicas Cnio Imidazopyrazines for use as kinase inhibitors
EP2451811A1 (en) 2009-05-27 2012-05-16 F. Hoffmann-La Roche AG Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
CA2761445A1 (en) * 2009-05-27 2010-12-02 Genentech, Inc. Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
GB0912745D0 (en) 2009-07-22 2009-08-26 Wolfson Microelectronics Plc Improvements relating to DC-DC converters
CN102762565A (zh) 2010-02-22 2012-10-31 弗·哈夫曼-拉罗切有限公司 吡啶并[3,2-d]嘧啶PI3δ抑制剂化合物及使用方法
CA2789475C (en) 2010-03-04 2018-05-29 Merck Sharp & Dohme Corp. Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
US9096605B2 (en) * 2011-08-24 2015-08-04 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as PI3 kinase inhibitors

Also Published As

Publication number Publication date
EP3277687A1 (en) 2018-02-07
EA201792087A1 (ru) 2018-03-30
JP6665201B2 (ja) 2020-03-13
PL236355B1 (pl) 2021-01-11
US20180111939A1 (en) 2018-04-26
PL3277687T3 (pl) 2020-09-21
US10138247B2 (en) 2018-11-27
AU2016241568B2 (en) 2019-09-26
EP3277687B1 (en) 2019-10-30
JP2018510192A (ja) 2018-04-12
KR102559190B1 (ko) 2023-07-25
WO2016157091A1 (en) 2016-10-06
DK3277687T3 (da) 2019-12-16
CN107743489A (zh) 2018-02-27
PT3277687T (pt) 2020-01-10
HUE047822T2 (hu) 2020-05-28
BR112017020131B1 (pt) 2023-02-28
PL411864A1 (pl) 2016-10-10
EA032826B1 (ru) 2019-07-31
MX2017011423A (es) 2018-05-17
SI3277687T1 (sl) 2020-02-28
HRP20192195T1 (hr) 2020-03-06
AU2016241568A1 (en) 2017-10-19
KR20170132275A (ko) 2017-12-01
ES2765642T3 (es) 2020-06-10
CA2978828A1 (en) 2016-10-06
CN107743489B (zh) 2021-05-04

Similar Documents

Publication Publication Date Title
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
BR112018007772A2 (pt) compostos de imidazo[4,5-c]quinolin-2-ona e seu uso no tratamento do câncer
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
CY1123627T1 (el) Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
PE20171307A1 (es) Compuestos de triazolopirimidina y usos de los mismos
EA201650029A1 (ru) Пиразолопиридины и пиразолопиримидины
AR078157A1 (es) Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
BR112015028501B8 (pt) Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
EA202090258A2 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ
BR112018007811A2 (pt) compostos de imidazo[4,5-c]quinolin-2-ona e seu uso no tratamento do câncer
EA201000090A1 (ru) Тризамещенные производные пиримидина для лечения пролиферативных заболеваний
BR112015015653A8 (pt) composto, método de preparação dos compostos, composto para uso, composição farmacêutica e métodos in vitro
PE20150637A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
BR112017016487A2 (pt) 7-benzil-4- (2-metilbenzil) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirrido [3,4-e] pirimidin-5 (1h) -ona, análogos desta, e sais do mesmo e métodos para sua utilização na terapia
CY1121060T1 (el) Παραγωγα [1,2,4] τριαζολο[1,5-α] πυριμιδινης ως αναστολεις πρωτεασωματος πρωτοζωων για τη θεραπεια παρασιτικων νοσηματων οπως η λεϊσμανιαση
EA201992090A1 (ru) ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
EA201991355A1 (ru) Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта
EA201790179A1 (ru) [1,2,4]триазоло[4,3-b]пиридазины для применения в лечении пролиферативных заболеваний
BR112021020297A2 (pt) Compostos de hexa-hidro-1h-pirazino[1,2-a]pirazina para o tratamento de doença autoimune
BR112018007392A2 (pt) derivados de 6-[5-amino-6-(2-etoxietóxi)-imidazo[4,5-b]piridin-3-il]-nicotinonitrila e seu uso como inibidores de irak
MX2019010756A (es) Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2).
BR112017020131A2 (pt) derivados de 7-(morfolin-4-il)pirazol[1,5-a]pirimidina que são úteis para o tratamento de doenças imunológicas ou inflamatórias ou câncer
EA202190036A1 (ru) Кристаллическая форма соединения для ингибирования активности cdk4/6 и ее применение

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/03/2016, OBSERVADAS AS CONDICOES LEGAIS